Immunic Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Daniel Vitt

Chief Executive Officer (CEO)

US$2.6m

Compensación total

Porcentaje del salario del CEO	20.3%
Permanencia del CEO	5yrs
Participación del CEO	0.4%
Permanencia media de la dirección	4yrs
Promedio de permanencia en la Junta Directiva	3.9yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Oct 13

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Jun 27

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Oct 20

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Daniel Vitt en comparación con los beneficios de Immunic?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$94m
Sep 30 2023	n/a	n/a	-US$129m
Jun 30 2023	n/a	n/a	-US$127m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$520k	-US$120m
Sep 30 2022	n/a	n/a	-US$85m
Jun 30 2022	n/a	n/a	-US$83m
Mar 31 2022	n/a	n/a	-US$79m
Dec 31 2021	US$2m	US$399k	-US$93m
Sep 30 2021	n/a	n/a	-US$83m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$70m
Dec 31 2020	US$1m	US$381k	-US$44m
Sep 30 2020	n/a	n/a	-US$41m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$39m
Dec 31 2019	US$2m	US$202k	-US$35m

Compensación vs. Mercado: Daniel($USD2.56M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: Danielha aumentado mientras la empresa no es rentable.

CEO

Daniel Vitt (55 yo)

5yrs

Permanencia

US$2,557,171

Compensación

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic, Inc. since April 2019 and also serves as its President. He is also managing director of Immunic Research GmbH in Halle (Saale). Dr. Vit...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Duane Nash	Executive Chairman	5.3yrs	US$1.07m	0.025% $ 30.6k
Daniel Vitt	CEO, President & Director	5yrs	US$2.56m	0.43% $ 543.3k
Glenn Whaley	Chief Financial Officer	4yrs	US$1.48m	0.028% $ 35.5k
Andreas Muehler	Chief Medical Officer	7.7yrs	US$1.46m	0.34% $ 424.4k
Hella Kohlhof	Chief Scientific Officer	7.3yrs	sin datos	sin datos
Jessica Breu	Head of Investor Relations & Communications	no data	sin datos	sin datos
Inderpal Singh	General Counsel	2.8yrs	sin datos	sin datos
Patrick Walsh	Chief Business Officer	2.5yrs	sin datos	sin datos

4.0yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: IMUXEl equipo directivo de la empresa se considera experimentado (3.7 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Duane Nash	Executive Chairman	5.3yrs	US$1.07m	0.025% $ 30.6k
Daniel Vitt	CEO, President & Director	5yrs	US$2.56m	0.43% $ 543.3k
Barclay Phillips	Lead Independent Director	4.4yrs	US$86.12k	0.012% $ 14.8k
Tamar Howson	Independent Director	4.5yrs	US$76.12k	0.012% $ 15.3k
Jorg Neermann	Independent Director	5yrs	US$78.62k	0.11% $ 139.0k
Paul Utz	Member of Scientific Medical Advisory Board	3.4yrs	sin datos	sin datos
Bruce Sands	Member of Scientific Medical Advisory Board	3.4yrs	sin datos	sin datos
Fred Lublin	Member of Scientific Medical Advisory Board	3.4yrs	sin datos	sin datos
Richard Rudick	Independent Director	less than a year	sin datos	0% $ 0
Monika Tornsen	Independent Director	1.8yrs	US$125.87k	0.0020% $ 2.5k

3.9yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de IMUX se considera experimentada (3.6 años de antigüedad promedio).

Immunic Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

Independent Director recently bought US$103k worth of stock

High number of new directors

Immunic, Inc. Announces Executive Changes

Executive Chairman recently bought US$50k worth of stock

High number of new directors

Recent updates

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026

New major risk - Financial position

Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts

Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis

New major risk - Share price stability

Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023

Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

High number of new directors

Price target decreased by 15% to US$18.00

Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Independent Director recently bought US$103k worth of stock

Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

High number of new directors

Price target decreased to US$21.17

Price target decreased to US$21.17

Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022

Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Price target increased to US$28.75

Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investors

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Price target decreased to US$22.40

Immunic GAAP EPS of -$0.72 in-line

Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic, Inc. Announces Executive Changes

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic Index

Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative Colitis

Price target decreased to US$49.43

Executive Chairman recently bought US$50k worth of stock

Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

Immunic, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of Its Phase I Clinical Trial of IMU-935

Immunic, Inc. Announces Enrollment of the First Patient in Its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2500 Growth Index

Executive Chairman recently bought US$51k worth of stock

We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely

Immunic EPS misses by $0.95

New 90-day low: US$14.80

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

New 90-day high: US$20.50

Iimmunic, Inc. Announces the Formation of a Scientific-Medical Advisory Board

Immunic EPS misses by $0.07

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19

Enrollment underway in Immunic's Phase 2 part of IMU-838 study in COVID-19

Immunic (IMUX) Investor Presentation - Slideshow